Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1065299 | 0.98 | ALDH1A1 (0.39) | ALDH1A1CHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL1062918 | 0.85 | ALDH1A1 (0.52) | ALDH1A1CHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL12933443 | 0.83 | ALDH1A1 (0.59) | ALDH1A1SOAT1MGAMGAASI | |
| SCHEMBL19945783 | 0.82 | CHRNB2 (0.40) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| Hydrochloric Acid SCHEMBL1066975 | 0.81 | ALDH1A1 (0.56) | ALDH1A1SOAT1MGAMGAASI | |
| Hydrochloric Acid SCHEMBL19924684 | 0.80 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRM2CHRM4CHRM5 | |
| SCHEMBL12933446 | 0.79 | CYP1A2 (0.41) | ALDH1A1CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19945790 | 0.79 | CHRNB2 (0.38) | ALDH1A1CHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL19927699 | 0.78 | PRMT3 (0.39) | ALDH1A1CHRNB2CHRNA4CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL19924643 | 0.78 | CHRNB2 (0.37) | ALDH1A1CHRNB2CHRNA4CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2016-05-12 | — | — | US | disclosed |
| US-8784885-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8784885-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20140186449-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2014-07-03 | — | — | US | disclosed |
| US-20140186448-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL (JP) | 2014-07-03 | — | — | US | disclosed |
| US-8722084-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8722084-B2 | Controlled release preparation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8449911-B2 | Drug composition having active ingredient adhered at high concentration to spherical core | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-8449911-B2 | Drug composition having active ingredient adhered at high concentration to spherical core | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20100285120-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100285120-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-11 | — | — | US | disclosed |
| US-20100278911-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100278911-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20100272798-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100272798-A1 | CONTROLLED RELEASE PREPARATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-28 | — | — | US | disclosed |
| US-7790755-B2 | dexlansoprazole FDA Orange book listed patent; capsules with pH dependently soluble polymers such as methyl methacrylate-methacrylic acid copolymers or cellulose esters | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| US-7790755-B2 | dexlansoprazole FDA Orange book listed patent; capsules with pH dependently soluble polymers such as methyl methacrylate-methacrylic acid copolymers or cellulose esters | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| US-7410981-B2 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-12 | — | — | US | disclosed |
| US-7410981-B2 | Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272798-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | ALDH1A1 3641/4885CHRNB2 2968/4885CHRNA4 2947/4885 |
| US-20160128945-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | ALDH1A1 3641/4885CHRNB2 2968/4885CHRNA4 2947/4885 |
| US-20100278911-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | ALDH1A1 3641/4885CHRNB2 2968/4885CHRNA4 2947/4885 |
| US-20100285120-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | ALDH1A1 3641/4885CHRNB2 2968/4885CHRNA4 2947/4885 |
| US-20140186449-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | ALDH1A1 3641/4885CHRNB2 2968/4885CHRNA4 2947/4885 |
| US-20140186448-A1 | CONTROLLED RELEASE PREPARATION | SLC18A1, MLN, GCG | ALDH1A1 3641/4885CHRNB2 2968/4885CHRNA4 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.